Skip to footer

$650 million settlement over marketing of blood thinner drug

$650 million settlement: German drugmaker Boehringer Ingelheim agreed to a $650 million settlement in a lawsuit involving 4,000 claims questioning the marketing and safety of Pradaxa.

|
(PRNewsFoto/Boehringer Ingelheim and AmeriCares Free Clinics)
President and CEO of Boehringer Ingelheim, J. Martin Carroll, celebrates the company's partnership with AmeriCares at the opening ceremony an AmeriCares Free Clinic in Danbury, Conn. The company settled a $650 million lawsuit over its Pradaxa product.
  • By Jim Suhr Associated Press

| East St. Louis, Ill.

German drugmaker Boehringer Ingelheim said Wednesday it has agreed to pay $650 million to settle thousands of U.S. claims questioning the marketing and safety of its popular blood thinner Pradaxa.

The company said the settlement, filed in federal court in East St. Louis, resolves roughly 4,000 claims, paying out an average of $162,500 per case.

The drug, known chemically as dabigatran, was approved in October 2010 by the U.S. Food and Drug Administration as a treatment intended to reduce the stroke risk in patients with irregular heartbeats, or atrial fibrillation. Pradaxa works by stopping the enzyme involved in blood clotting.

But the plaintiffs had argued the company didn't adequately warn Pradaxa users of the risks, including severe or in many cases fatal bleeding blamed on the anticoagulant. Unlike other blood-thinning medications, those behind the lawsuits said, there is no known reversal agent or antidote for Pradaxa, an alternative to decades-old warfarin.

Boehringer Ingelheim, based in Ingelheim, Germany, stands "resolutely" behind Pradaxa "and believed from the outset that the plaintiffs' claims lacked any merit," the company's global general counsel said in a statement.

"Time and again the benefits and safety of Pradaxa have been confirmed in many clinical trials and in real-world data analyses," Andreas Neumann added. "This settlement does not change the facts about Pradaxa or its importance to patients."

But Neumann said the deal eliminates the distraction and uncertainty of possibly years of litigation in the U.S. court system.

"Furthermore, we have to consider that juries composed of lay people have to decide about very difficult scientific matters," Neumann said. "All this does not allow reliable predictions for the outcome of a huge number of individual trials, and that is why we came to the tough decision to settle."

Roger Denton, one of the plaintiffs' attorneys, said the settlement was "an outstanding result and is in the best interests of our clients who have suffered serious injuries after using Pradaxa."

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

You've read  of  free articles. Subscribe to continue.
Real news can be honest, hopeful, credible, constructive.
What is the Monitor difference? Tackling the tough headlines – with humanity. Listening to sources – with respect. Seeing the story that others are missing by reporting what so often gets overlooked: the values that connect us. That’s Monitor reporting – news that changes how you see the world.
editor@csmonitor.com
Subscribe
Mark Sappenfield
Editor

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to CSMonitor.com.

Subscribe to insightful journalism

QR Code to $650 million settlement over marketing of blood thinner drug
Read this article in
https://www.csmonitor.com/Business/Latest-News-Wires/2014/0529/650-million-settlement-over-marketing-of-blood-thinner-drug
QR Code to Subscription page
Start your subscription today
https://www.csmonitor.com/subscribe